PHENETRON Drug Patent Profile
✉ Email this page to a colleague
When do Phenetron patents expire, and when can generic versions of Phenetron launch?
Phenetron is a drug marketed by Lannett and is included in one NDA.
The generic ingredient in PHENETRON is chlorpheniramine maleate. There are twenty-nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the chlorpheniramine maleate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Phenetron
A generic version of PHENETRON was approved as chlorpheniramine maleate by AVANTHI INC on May 13th, 2009.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PHENETRON?
- What are the global sales for PHENETRON?
- What is Average Wholesale Price for PHENETRON?
Summary for PHENETRON
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 46 |
| Patent Applications: | 4,308 |
| DailyMed Link: | PHENETRON at DailyMed |
US Patents and Regulatory Information for PHENETRON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lannett | PHENETRON | chlorpheniramine maleate | TABLET;ORAL | 080846-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
